Canada Antibacterial (Antibiotics) Drugs Market is at around $4.07 Bn in 2023 and is projected to reach $5.4 Bn in 2030, exhibiting a CAGR of 4.2% during the forecast period. The market is being driven by factors such as the rise in infectious disease incidence, the expansion of healthcare infrastructure, and the increase in awareness and education. The market is dominated by key players like Pfizer Canada, GlaxoSmithKline (GSK), Johnson & Johnson Inc. (J&J), Merck Canada, Abbott Laboratories Limited, Astra Zeneca Canada, Sanofi Canada, Novartis Pharmaceuticals Canada Inc., Eli Lilly Canada Inc., and F. Hoffmann-La Roche Ltd.
Canada's clinical diagnostics is expected to witness significant growth from $3.9 Bn in 2022 to $4.9 Bn in 2030 with a CAGR of 3.1% for the year 2022-30. The main growth drivers of the Canadian clinical diagnostics market are growing awareness about early disease detection and the benefits of early treatment. Further, the increasing investments by the government in diagnostic services are responsible for the market growth. The market is segmented by molecular diagnostics and end users. LifeLabs, SickKids, and Dynacare are some of the top players in this market.
Canada's physiotherapy market size was valued at $4.25 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.85% from 2022 to 2030 and will reach $6.70 Bn in 2030. The Canada physiotherapy market is expected to grow due to an increase in the number of people suffering from chronic conditions including diabetes and obesity as well as an aging population. The market is segmented by Product Type, Application Type, and End User. The major players in the Canada physiotherapy market are BTL Industries, Performance Health, ITO Co., Ltd., Enraf-Nonius B.V., and others.
Canada's biosimilar market size was valued at $1.53 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 22.2% from 2022 to 2030 and will reach $7.63 Bn in 2030. The market is segmented by product type and indication type. This market will grow as there is a shortage of qualified radiologists and imaging technologists in some areas, leading to longer wait times and delays in diagnosis and treatment. The key market players are Sonic Healthcare Limited Amgen, Biocon, Celltrion Healthcare, Dr. Reddy's Laboratories, and others.
The legalization of medical cannabis in Canada has resulted in the growth of Canada cannabis for GI diseases market. Cannabis can be used to treat irritable bowel disease, inflammatory bowel diseases, and colitis. The market is segmented by application and by product type.
The Canada dermatology prescription market is projected to grow from $459.7 Mn in 2022 to $927.4 Mn in 2030 with a CAGR of 9.2% for the year 2022-2030. Technological advancements and a strong pipeline of drugs are the possible market drivers for the growth of the market during the forecast period.
Canada's dermatology prescription market is expected to grow from $459.7 Mn in 2022 to $927.4 Mn in 2030 with a CAGR of 9.2% for the year 2022-30. Rising incidences of dermatology disorders involving the skin, nails, hair, etc, and the demand for novel therapeutics for the treatment of dermatology disorders in Canada are major market drivers of the Canadian dermatology prescription market. the market is segmented by disease type, drug class, route of administration, end-user, and by distribution channel. Affinium, Pfizer, and Sanofi are some of the key players in Canada's dermatology prescription market.
This report presents a strategic analysis of the Canada Retail Pharmacy Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Canada Retail Pharmacy Market, offering unmatched value, accuracy and expert insights.
Canada's cardiac monitoring device market is likely to grow at a CAGR of 4.7% from a market size of $2.31 Bn in 2022 to $3.34 Bn in 2030. The main key factor driving the market is the penetration of smart technology in cardiac monitoring devices and the increasing prevalence of cardiac diseases. This report is segmented by product type and by the end user. Some key players in this market include Medtronic, Abbott, Koninklijke Philips, Boston Scientific Corporation, GE Healthcare, Hill-Rom Holdings, Schiller, and others.
This report presents a strategic analysis of the Canada Patient Support Programs (PSP) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Canada Patient Support Programs (PSP) Market, offering unmatched value, accuracy and expert insights.
Canada's healthcare claims management market is likely to grow at a CAGR of 23.4% from a market size of $2.13 Bn in 2022 to $11.48 Bn in 2030. The rise in research and development expenditure in healthcare along with the new technological advancements and the increasing trend of automation in healthcare acts as a growth factor for the market. This report is segmented by component, type, delivery mode, and by end user. Some key players in this market include Accenture, Allscripts, Cerner, AthenaHealth, McKesson, IBM Corporation, and others.
The Canada digital health market is projected to grow from $16.88 Bn in 2022 to $66.07 Bn in 2030 with a CAGR of 18.6% for the year 2022-2030. Many companies in Canada are entering into a digital pace focussed on providing accessibility, quality, and efficient treatments in Canada. The market is segmented by technology, end users and components.